Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of CYTK will decline by -4.94% over the next 2 Weeks and hit $76.64 by Monday, August 10, 2026. In that time frame, CYTK's share price is expected to range between $74.01 and $79.44.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Aug 10, 2026 | 74.01 | 76.64 | 79.44 |
| Aug 7, 2026 | 75.66 | 78.07 | 80.37 |
| Aug 6, 2026 | 75.90 | 78.27 | 80.65 |
| Aug 5, 2026 | 75.89 | 78.36 | 80.63 |
| Aug 4, 2026 | 76.23 | 78.33 | 80.49 |
| Aug 3, 2026 | 75.96 | 78.30 | 80.51 |
| Jul 31, 2026 | 77.59 | 79.73 | 81.96 |
| Jul 30, 2026 | 77.98 | 79.93 | 81.91 |
| Jul 29, 2026 | 77.83 | 80.02 | 81.99 |
| Jul 28, 2026 | 78.00 | 80.00 | 82.11 |
CYTK shares fell -1.45% in Tuesday, July 28, 2026's trading session, dropping from a previous close of $80.62 to move at $79.45. The stock demonstrated notable intraday movement (see CYTK's key stats for a full breakdown), fluctuating between $79.00 and $81.02, a +2.56% trading range. While recent weeks have seen some volatility, CYTK has managed to secure a -3.84% drop over the past 2 weeks. The downward price movement was accompanied by decreased trading volume, with approximately 1.63M shares changing hands, 205.14K fewer than the previous session. This amounted to $129.50M in total market activity.
Will CYTK Continue Its Downward Trend?
According to analyst ratings and projections for CYTK, Cytokinetics, Incorporated shares are anticipated to decrease by -0.02%, potentially reaching $79.44 per share by August 10, 2026. Short-term technical indicators currently suggest a neutral sentiment for CYTK. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 15 positive trading days within the past 30 sessions. Based on the CYTK stock forecast, now is not the best time to buy CYTK stock because its current trading price is +3.67% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on CYTK covering social and institutional perspectives.
CYTK Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into CYTK's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 39.29% to 49.91%) suggest mixed signals, with the stock in a neutral to slightly bearish momentum phase. The 50-day RSI, at 54.12%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 54.49%, maintains a neutral outlook for the long term. Insights into CYTK's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Cytokinetics Short-Term Forecasts
CYTK Forecast For Next 5 Days
Our algorithm anticipates Cytokinetics (CYTK) stock could hit $85.37 by Aug 04, 2026. This represents a +7.45% fall from today's price, following a -1.33% change over the past five days.
CYTK Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Cytokinetics, Incorporated (CYTK) stock over the next 30 days is largely positive. Price forecasts suggest an average target of $86.32, which would mean a +8.65% increase from the current price of $79.45. Projections for this period range from a high of $95.27 to a low of $76.70.
CYTK Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Cytokinetics's price over the next three months point to a drop. CYTK stock is expected to peak at $85.17 on Jul 28, 2026 before potentially dipping to $70.40 on Aug 05, 2026. On average, CYTK is likely to trade around $77.58 in the coming 90 days.
Cytokinetics Stock Forecast 2025
Based on our predictive models, Cytokinetics (CYTK) is expected to trade between $69.93 and $91.27 throughout 2026. This would result in an average price of $79.33, potentially offering investors a -0.15% return from current levels.
Cytokinetics, Incorporated Monthly Forecast 2026–2027
July 2026
According to our latest forecast models, Cytokinetics, Incorporated (CYTK) is positioned to show a strong performance in July 2026. The price is predicted to move between $72.85 and $85.17, settling at an average of $79.12. This could translate to a -0.42% loss.
August 2026
Based on current market signals, Cytokinetics, Incorporated is projected to trend august 2026. We forecast a trading range from $70.40 to $84.13, with a likely average price of $76.92. Investors could expect a potential return of -3.18%.
September 2026
Our predictive algorithms indicate Cytokinetics, Incorporated stock may see a shift in September 2026. The expected range spans $71.06–$84.71, with an average target of $77.84. This represents a cautious outlook and a possible loss of -2.03%.
October 2026
Analyzing established trends, Cytokinetics, Incorporated looks set to move in October 2026. Projections place the stock between $70.42 and $83.83, averaging around $77.53. This suggests a -2.42% loss from current levels.
November 2026
Market indicators suggest Cytokinetics, Incorporated could experience notable changes during November 2026. Prices could fluctuate within $69.93 to $91.27, with a midpoint forecast of $80.96. The stock might deliver a +1.90% gain.
December 2026
Forecasting for December 2026, models estimate that Cytokinetics, Incorporated may undergo key fluctuations. If trends hold, the stock might trade between $73.79 and $91.09, averaging $83.20. This signals a positive trajectory with potential returns around +4.72%.
January 2027
According to our latest forecast models, Cytokinetics, Incorporated (CYTK) is positioned to show a strong performance in January 2027. The price is predicted to move between $72.83 and $86.98, settling at an average of $79.67. This could translate to a +0.28% gain.
February 2027
Based on current market signals, Cytokinetics, Incorporated is projected to trend february 2027. We forecast a trading range from $73.99 to $87.57, with a likely average price of $80.69. Investors could expect a potential return of +1.56%.
March 2027
Our predictive algorithms indicate Cytokinetics, Incorporated stock may see a shift in March 2027. The expected range spans $72.29–$86.61, with an average target of $80.24. This represents a positive outlook and a possible gain of +0.99%.
April 2027
Analyzing established trends, Cytokinetics, Incorporated looks set to move in April 2027. Projections place the stock between $73.43 and $94.25, averaging around $83.88. This suggests a +5.58% gain from current levels.
May 2027
Market indicators suggest Cytokinetics, Incorporated could experience notable changes during May 2027. Prices could fluctuate within $76.48 to $93.82, with a midpoint forecast of $85.95. The stock might deliver a +8.18% gain.
June 2027
Forecasting for June 2027, models estimate that Cytokinetics, Incorporated may undergo key fluctuations. If trends hold, the stock might trade between $75.15 and $89.73, averaging $82.40. This signals a positive trajectory with potential returns around +3.71%.
July 2027
According to our latest forecast models, Cytokinetics, Incorporated (CYTK) is positioned to show a strong performance in July 2027. The price is predicted to move between $77.42 and $90.02, settling at an average of $83.48. This could translate to a +5.07% gain.
CYTK's history of dividends and stock splits also plays a role in long-term investor confidence.